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a b s t r a c t
-Amanitin is a natural bicyclic octapeptide, from the family of amatoxins, present in the deadly mush-
room species Amanita phalloides. The toxicological and clinical interests raised by this toxin, require
highly sensitive, accurate and reproducible quantiﬁcation methods for pharmacokinetic studies. In the
present work, a high-performance liquid chromatographic (HPLC) method with in-line connected diode-
array (DAD) and electrochemical (EC) detection was developed and validated to quantify -amanitin in
biological samples (namely liver and kidney). Sample pre-treatment consisted of a simple and unique
deproteinization step with 5% perchloric acid followed by centrifugation at 16,000× g, 4 ◦C, for 20min.
Thehigh recovery found for-amanitin (≥96.8%)makes this procedure suitable for extracting-amanitin
from liver and kidney homogenates. The resulting supernatant was collected and injected into the HPLC.
Mobile phase was composed by 20% methanol in 50mM citric acid, and 0.46mM octanessulfonic acid,
adjusted to pH 5.5. The chromatographic runs took less than 22min and no signiﬁcant endogenous inter-
ferences were observed at the -amanitin retention time. Calibration curves were linear with regression
coefﬁcients higher than 0.994. The overall inter- and intra-assay precision did not exceed 15.3%.
The present method has low interferences with simple and fast processing steps, being a suitable
procedure to support in vivo toxicokinetic studies involving-amanitin. In fact, the validatedmethodwas
successfully applied to quantify -amanitin in biological samples following intraperitoneal -amanitin
administration to rats. Moreover, human plasma was also used as matrix and the purposed method
was adequate for detection of -amanitin in that matrix. The results clearly indicate that the proposed
method is suitable to investigate the pharmacokinetic and tissue distribution of-amanitin. Additionally,
the method will be very useful in the development of novel and potent antidotes against amatoxins
poisoning and to improve the knowledge of -amanitin toxicity.
© 2015 Elsevier B.V. All rights reserved.
1. Introduction
The main toxin of the amatoxins group, -amanitin (Fig. 1) is a
toxic bicyclic octapeptide present in the deadly mushroom species
Amanita phalloides. It represents up to 40%of the amatoxins present
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array; EC, electrochemical; DNA, deoxyribonucleic acid; LOD, limit of detection;
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RNA, ribonucleic acid; RNAP II, RNA polymerase II; RSD, relative standard deviation;
SPE, solid phase extraction; UV, ultraviolet.
∗ Corresponding authors. Fax: +351 22609339.
E-mail addresses: jugarcia 18@hotmail.com (J. Garcia), felixdc@ff.up.pt
(F. Carvalho).
in this mushroom and is the main responsible for its toxic effects
[1]. -Amanitin produces hepatic and kidney failure, which result
in a potentially fatal outcome in most of the human intoxication
cases [2]. The underlying toxicity mechanisms of -amanitin are
not completely understood, but it is well accepted that the inhi-
bition of RNA polymerase II (RNAP II) is its main effect [3] . Other
mechanisms also appear to be involved, including oxidative stress
[4].
So far, there is no speciﬁc and totally effective antidote
against A. phalloides poisoning. Benzylpenicillin, ceftazidime, N-
acetylcysteine, and silybin are themost extensively used antidotes,
however mortality remains high [5]. Currently, in vivo and in silico
studies are ongoing in search of effective antidotes, either directed
to the toxicokinetics or to the toxicodynamics of amatoxins [6–9]
http://dx.doi.org/10.1016/j.jchromb.2015.06.001
1570-0232/© 2015 Elsevier B.V. All rights reserved.
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Fig. 1. Chemical structure of -amanitin.
. In both approaches, it is expected that the development of more
insightful analytical and physiological methodologies will provide
essential tools for achieving this purpose.
Besides the toxicological interest in -amanitin, recent ﬁndings
indicate that -amanitin is emerging as an attractive new class
of potent anticancer drug [10]. For this clinical application, ade-
quate analyticalmethodologies are also required for the evaluation
of -amanitin pharmacokinetics, both in pre-clinical and clinical
studies.
The comprehensive characterization of antidotes in A. phal-
loides poisoning and the pharmacokinetics and toxicokinetic
studies of -amanitin require highly sensitive, accurate and
reproducible quantiﬁcation assays. Currently, there are several
high-performance liquid chromatography (HPLC)–ultraviolet (UV)
[11–17], liquid chromatography (LC)–mass spectrometry (MS)
[18–20] and ultra performance liquid chromatography (UPLC)-
MS/MS [21]methods to determine-amanitin inmushrooms, liver
and biological ﬂuids (Table 1). HPLC-MS methods for -amanitin
detection are accurate, sensitive, and speciﬁc; nevertheless HPLC-
MS is an expensive technique and is not available in many
laboratories. To date there are no published HPLC with electro-
chemical (EC) detection methods for the analysis of -amanitin in
biological tissues. Hence, in this paper, we describe a simple acidic
extraction and HPLC methodology with in-line connected photodi-
ode array detection (DAD) and EC detection to quantify-amanitin
in rat liver and kidney. Moreover, we applied the validated method
to identify -amanitin in human plasma. The validated method
was successfully applied to quantify -amanitin in plasma, liver
and kidney tissues following intraperitoneal administration to rats.
The new method provides the required high analytical sensitivity
and reproducibility, with a simple and fast pretreatment, as it is
required for advanced pharmacokinetic and toxicokinetic research.
2. Material and methods
2.1. Reagents and chemicals
-Amanitin (>99%), bovine serum albumin, and 1-
octanesulfonic acid sodium salt were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Analytical HPLC grade
methanol was obtained from Fisher Scientiﬁc (Waltham, Mas-
sachusetts, USA). Sodium chloride (NaCl), potassium chloride
(KCl), sodium hydrogen phosphate (Na2HPO4), potassium dihy-
drogen phosphate (KH2PO4) and 60% (m/v) perchloric acid were
purchased from Merck (Darmstadt, Germany). Water was puriﬁed
with a Milli-Q Plus ultra-pure water puriﬁcation system (Millipore,
Bedford, Massachusetts, USA).
2.2. Chromatographic conditions
HPLC analysis was performed using a Waters 2690 separa-
tion module (Waters, Milford, MA, USA), and a 250mm×4.6mm,
Waters Spherisorb RP-18 (5m) ODS2 column. The mobile phase
(20% methanol in 50mM citric acid, 0.46mM octanessulfonic acid,
adjusted to pH5.5with 10MNaOH)was ﬁltered through a 0.45m
membrane (Millipore, Madrid, Spain) and degassed. An isocratic
elutionwasperformedat aﬂowrateof1.0mL/min, at roomtemper-
ature. Sample aliquots of 20L were injected. A Compaq computer
ﬁtted with Millenium32 software (Waters) processed the chro-
matographic and spectral data.
For the spectroscopic and coulochemical analysis, a photodi-
ode array detector (Waters model 996) and/or a Colouchem II
(ESA, Chelmsford, USA) equipped with a guard cell (ESA 5020) and
analytical cell (ESA 5011A) electrochemical detector were used.
In all the studies, both detectors were used, with the analytical
cell of the coulochemical detector placed after the photodiode
arraydetector. Theelectrochemicalpotential settingsofCoulochem
II detector were: guard cell, −550mV, and analytical detector +
500mV, following a previous reported procedure [22]. A current
of 5A full-scale was used. Ultraviolet-visible spectra were col-
lected for all samples between from230 to 400nm. For quantitative
analyses, chromatograms were integrated at 305nm [15].
2.3. Stock solution and calibration standards
A stock solution of -amanitin was prepared in water Milli-Q
and diluted to a ﬁnal concentration of 1mg mL−1. All stock solu-
tions were stored of −20 ◦C. A set of eleven standards ranging from
0.025g mL−1 to 10g mL−1 were prepared at the moment of
use by spiking the rat liver and kidney samples with appropriate
amounts of -amanitin. All calibration standards were prepared in
triplicate.
2.4. Animals and sample preparation
The liver and kidney tissues were obtained from adult male
Wistar rats. These animals were used as healthy controls in other
experiments, where liver and kidney were not necessary. A mini-
mum number of animals was used in order to obtain valid results.
All experiments were approved by local ethical committee. All rats
were between 5 and 6 weeks of age and weighting about 150 to
J. Garcia et al. / J. Chromatogr. B 997 (2015) 85–95 87
Table 1
Liquid chromatographic methods for - amanitin analysis in different matrices.
LOD LOQ
Method Matrix ngmL−1 ng g−1 ngmL−1 ng g−1 References
HPLC–UV Mushrooms 10 ns [15]
HPLC–UV Serum 6 3 [31]
HPLC–UV Plasma 5 [29]
Urine 5
Gastroduodenal 5
ﬂuid
Liver 5
Kidney 5
HPLC–UV Serum 10 ns [16]
Urine 10 ns
Stomach washings 10 ns
LC–MS/MS/MS Serum 0.26 ns [19]
Liver 0.5 ns
HPLC–EC Urine 2 10 [22]
LC–MS/MS Plasma 0.5 ns [20]
LC–MS/MS Mushrooms 20 15.1 [18]
HPLC–EC Plasma 2 ns [28]
LC–MS Urine 2.5 5 [32]
UPLC–MS/MS Urine 0.22 0.46 [21]
Liver 10.9 14.7
ns: not speciﬁed.
200g. Rats were sacriﬁced by guillotine decapitation by an experi-
enced veterinarian and liver and kidney tissues were immediately
collectedandkept frozenat−20 ◦Cuntil homogenization.Onegram
of each organ was homogenized using an Ultra-Turrax homoge-
nizer in 4mL of 0.1M phosphate buffer, pH 7.4. The homogenate
was placed in perchloric acid (5% ﬁnal concentration) in the ratio
1:2 for protein denaturation, and centrifuged at 16,000× g, 4 ◦C for
20min. The resulting supernatant was collected and injected into
theHPLC before or after spikingwith-amanitin, depending on the
condition to be tested.
2.5. Method validation
The HPLC method with simultaneous DAD and EC detection
for the determination of -amanitin in 5% perchloric acid, and
in liver and kidney samples was validated by the evaluation of
the following parameters: speciﬁcity, linearity, recovery, precision,
sensitivity, matrix effect and analyte stability.
2.5.1. Speciﬁcity
Speciﬁcity is the ability to assess unequivocally the analyte in
the presence of components that may be expected to be present in
that matrix [23]. Speciﬁcity of the method was tested by analysis
of three different blanks: 5% perchloric acid, rat liver and kid-
ney extracts and compared to samples spiked with 5g mL −1 of
-amanitin toensure theabsenceof compoundswith similar reten-
tion times. The purity of the peak of -amanitin was investigated
bydetermining theultraviolet andvisible spectrumwithmaximum
absorbance using the DAD and by comparing the retention times
between spiked samples and pure controls.
2.5.2. Linearity
The linearity of an analytical procedure is its ability to obtain
test results that are directly proportional to the concentration of
analyte in the sample within a given range [23]. The linearity
response for -amanitin was initially studied using eleven stan-
dards in 5% perchloric acid injected three times, covering the range
of0.025–10gmL−1. Subsequently, linearitywas studied inbiolog-
ical samples spiked with a series of -amanitin standards covering
the mentioned range. The linearity was evaluated by linear regres-
sion analysis.
2.5.3. Recovery
Typically, the accuracy of the analytical methods is determined
by recovery studies done by spiking the blank matrix with the ana-
lyteprior to sample treatment [24] . Therefore, recoverywasused to
further evaluate the accuracy of the method in our study. To deter-
mine method accuracy, different concentrations of -amanitin
(low, medium and high) were used to spike blank liver and kid-
ney samples (n=3). After homogenization, known concentrations
of -amanitin were added to three different rat liver and kidney
preparations placed in 0.1M phosphate buffer. The ﬁnal hepatic
homogenate concentrations used to assess low, medium and high
concentrations were: 0.5, 5, and 7.5gmL−1 of -amanitin. The
ﬁnal renal homogenate concentrations used to assess low,medium
and high concentrations were: 0.82, 5, and 7.5g mL−1 of -
amanitin. After vortexing for 1min, the homogenates were placed
in perchloric acid (5% ﬁnal concentration). Centrifugation followed
for 10min at 16,000× g, the supernatants being collected and
injected in the HPLC. The recoveries were assessed by comparing
the peak area of the -amanitin extracted from liver and kidney
homogenates to those of blank deproteinized liver and kidney sam-
ples spiked with similar concentrations and injected in the same
day and HPLC conditions.
2.5.4. Precision
Precision expresses the degree of scatter between a series of
measurementsobtained frommultiple samplingof the samehomo-
geneous sample. Precision may be considered at three levels:
repeatability, intermediate precision, and reproducibility [23]. In
thiswork,method precision (intra-assay repeatability), instrument
precision (injection repeatability), and intermediateprecisionwere
investigated. To determine method precision (intra-assay), differ-
ent concentrations of-amanitin (low,middle and high)were used
by spiking blank hepatic and renal samples and performing several
replicates (n=6). Known concentrations of-amanitin were added
to biological matrices to obtain ﬁnal liver matrix concentrations of
0.5 (low), 5 (medium) and 7.5g mL−1 (high) and kidney matrix
concentrations of 0.82 (low), 5 (medium) and 7.5g mL−1 (high).
The samples were analyzed by the same analyst and in the same
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day. Intermediate precision was also studied in order to determine
the agreement of the measurements when the method was used
on different days. The inter-assay precision was determined by the
analysis of the sameconcentrations of-amanitin used in the intra-
assay study through the injection of six replicates on three different
days over a period of three weeks. The precision was reported as
the relative standard deviation (% RSD). The% RSD of the proposed
method was calculated using the following equation: %RSD= S/x
where S is the standard deviation and x is the mean of response.
2.5.5. Sensitivity
The limit of detection (LOD) of an analytical procedure is the
lowest concentration of an analyte in a sample, which can be
detected but not necessarily quantitated as an exact value. The
limit of quantiﬁcation (LOQ) is the lowest amount of analyte in a
sample that can be quantitatively determined with suitable preci-
sion and accuracy [23]. The LOD and LOQ were calculated by using
standard solutions prepared in 5% perchloric acid, liver and kid-
ney samples. Two different criteria were applied. Firstly, the LOD
and LOQ were measured based on visual evaluation according to
International Conference onHarmonization Q2 (ICHQ2) guidelines
[25], by successively diluting a stock solution containing 1mgmL−1
of -amanitin. The minimum concentrations of -amanitin that
were reliably detected andquantiﬁedwith acceptable accuracy and
precisionwere considered the LOD and LOQ of ourmethod, respec-
tively. Additionally, the LOD and LOQ were determined using the
calibration curve method described in the same guidelines [25].
The LOD (k=3.3) and LOQ (k=10) were calculated using the fol-
lowing equation: A= k/S, where A is LOD or LOQ,  is the standard
deviation of the response, and S is the slope of the calibration curve.
2.5.6. Evaluation of the matrix effect
The matrix effect was evaluated by comparing the calibration
graphs obtained by spiking liver and kidney samples with known
amounts of -amanitin, and the calibration graph was obtained
from standard -amanitin 5% perchloric acid solutions.
2.5.7. Analyte stability
A stability study was performed in order to assess the stabil-
ity of the analyte, in different storage and analysis conditions.
-Amanitin stability experiments’ were evaluated in 5% perchlo-
ric acid, and in deproteinized liver and kidney samples. Perchloric
acid (5%) and blank liver and kidney samples were divided into
four aliquots, and each aliquot was spiked with -amanitin at
2.5g mL−1. Final concentration of each sample was analyzed
immediately, while the remaining samples were stored at room
temperature, 4 ◦C, −20 ◦C and −80 ◦C and thereafter analyzed after
24h, 7, 14 days without any other freeze-thaw cycles.
Stability was also studied after several freeze–thaw cycles. Per-
chloric acid (5%), blank liver and kidney samples were divided
into two aliquots, each aliquot was spiked with -amanitin at
2.5gmL−1 and stored at −20 ◦C and −80 ◦C. These samples were
analyzed after three freeze–thaw cycles at room temperature. All
samples used for stability testing were tested in triplicate. A stan-
dard curve was constructed during each analytical evaluation and
injected in the same day and conditions.
2.6. Method application
The described analytical method was applied to four different
human plasma samples. Aliquots of these plasma samples were
spiked with -amanitin to a ﬁnal concentration of 5g mL−1
followed by deproteinization using perchloric acid (5% ﬁnal con-
centration). The dispersion was vortexed for 1min and then the
samples were centrifuged at 16,000× g for 10min at 4 ◦C. The
supernatants were then collected and injected into the HPLC sys-
tem.
2.7. In vivo validation of the method
Female Wistar rats were used as the animal model for in vivo
experiments. Animals were obtained from vivarium of Institute of
Biomedical Sciences - ICBAS, University of Porto and were between
120and150gat the timeof experiment. Theprotocolwas approved
by the local committee for the welfare of experimental animals
and was performed in accordance with national legislation. Rats
received-amanitin (dissolved in saline solution) intraperitoneally
at a dose of 10mg kg−1 and 21.4mg kg−1 for different time-points.
After two or four hours, the animals were anesthetized with isoﬂu-
rane and sacriﬁced by exsanguination, collecting the blood in the
inferior vena cava into EDTA- containing tubes. Plasmawas isolated
from blood by centrifugation at 920× g for 10min at 4 ◦C. Liver
and kidneys were removed, weighed, and homogenized in ice-cold
0.1M phosphate buffer, pH 7.4. An aliquot of the homogenate was
stored (−20 ◦C) for posterior protein quantiﬁcation. An aliquot of
the homogenate was placed in perchloric acid (5% ﬁnal concentra-
tion) for protein denaturation, and centrifuged at 16,000×g, 4 ◦C
for20min. The supernatantwas thencollectedand injected into the
HPLC system. A set of eleven standards ranging from0.025gmL−1
to 10g mL−1 were prepared at the moment of use by spiking rat
liver and kidney samples with appropriate amounts of-amanitin,
as described before. The -amanitin levels in plasma, liver and
kidney at 2 and 4h after administration were determined. As to
conﬁrm the identity of the -amanitin peak, samples were spiked
with a standard solution of 5g mL−1 of -amanitin.
2.7.1. Protein determination
Protein content was determined by the method described by
Lowry [26]. Bovine serum albumin was used as protein standard.
Fifty L of samples, standards or blank were added in triplicate to
a 96-well microtiter plate, followed by addition 100L of extem-
poraneously prepared Reagent A (9.8mL of 2% sodium carbonate,
100L of 2% sodium potassium tartrate and 100L of 1% sulfate
cupper II). After 10min under light protection, 100L of extempo-
raneously prepared Reagent B (Folin–Ciocalteu reagent and H2O,
1:14) was added. The microtiter plate was kept protected from
the light for 20min, after which the absorbance was measured at
750nm.
2.8. Statistical analysis
The linearity was evaluated by the linear regression test. Eval-
uation of the matrix effect was performed by one-way analysis
of variance to determine the statistical signiﬁcance between the
slopes of the 5% perchloric acid, liver and kidney standard cal-
ibration curves. Statistical signiﬁcance was set at p<0.05. The
Tukey multiple comparisons test was used once a signiﬁcant p was
achieved. In the evaluation of stability, different conditions were
assessed in different time-points, thus a two-way analysis of vari-
ance was performed. If a statistical signiﬁcant effect was found
(p<0.05), the Tukey multiple comparisons test was performed. All
statistical tests were performed using GraphPad Prism version 6
(San Diego, California, USA).
3. Results
3.1. Optimization of the chromatographic conditions
In order to obtain low background noise in the biological matri-
ces, citric acid/methanolwas used asmobile phase, as citrate can be
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Fig. 2. Representative chromatograms recorded at 305nm (A) of blank 5% perchloric acid and 5% perchloric acid spiked to contain 5g mL−1 of -amanitin; (B) blank
liver, and liver sample spiked to contain 5gmL−1 of - amanitin and (C) blank kidney, and kidney sample spiked to contain 5gmL−1 of -amanitin. Representative
electrochemical chromatograms of (D) blank 5% perchloric acid and 5% perchloric acid spiked to contain 5g mL−1 of -amanitin; (E) blank liver, and liver sample spiked to
contain 5gmL−1 of - amanitin and (F) blank kidney, and kidney sample spiked to contain 5gmL−1 of - amanitin.
used in a wide range of pH (2.1 <pH<6.4) and provides low back-
ground noise [24,27]. It was observed that the ratio of citric acid
and methanol (80:20) was key to a good separation and resolution
of the peaks. The pH value was also studied as it has an important
role in the resolution of complex mixtures as homogenates. Thus
it is also important to properly adjust the pH of the mobile phase.
For this purpose, a pH of 5.5 was chosen, since it gave the best
chromatographic resolution and the sharpest peaks. Moreover, the
octanessulfonic acid, an ion pairing reagent, leads to an enhanced
resolution of the -amanitin peak. Taken together, the optimiza-
tion of the mobile phase and pH led to an optimal chromatographic
resolution of the sample components and a low chromatographical
run (22min) (Fig. 2).
3.2. Sample preparation
The main goal of the sample preparation was to create a simple
method that allowed the elimination of interferences and good sta-
bilityof theanalyte,-amanitin. Liver andkidneyarequite complex
matrices, with high level of proteins, thus, a good deproteinizing
step was required. For this purpose, we used perchloric acid (5%
ﬁnal concentration). After centrifugation, the resulting supernatant
can be directly injected into HPLC, therefore resulting in a simple
procedure that can be performed in all laboratory settings.
3.3. Method validation
3.3.1. Speciﬁcity
The speciﬁcity of the assay was examined using the described
chromatographic conditions on Section 2. Representative chro-
matograms recorded at 305nmof blank 5% perchloric acid and a 5%
perchloric acid spiked to contain 5gmL−1 of- amanitin (Fig. 2A),
blank liver sample anda liver sample spiked to contain5gmL−1 of
- amanitin (Fig. 2C) and a blank kidney sample and a kidney sam-
ple spiked to contain 5g mL−1 of -amanitin (Fig. 2E) are shown
in Fig. 2. Representative electrochemical (EC) chromatograms of
blank5%perchloric acid andaperchloric acid spiked to contain5g
mL−1 of -amanitin (Fig. 2B), blank liver sample and a liver sample
spiked to contain 5g mL-1 of -amanitin (Fig. 2D) and a blank
kidney sample and a kidney sample spiked to contain 5g mL−1
of - amanitin (Fig. 2F) are also shown. There were no endogenous
interfering substances in the samples at the same retention time of
-amanitin.
3.3.2. Linearity
The linear least squares regression equation (1/c2) correlation
coefﬁcients of the standard curves for -amanitin in 5% perchloric
acid, and for liver and kidney extractswere all above 0.994. The lin-
ear equations and corresponding coefﬁcient of determination (r2)
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Table 2
Linearity data of -amanitin analysis in 5% perchloric acid and tissue samples.
Linear equation Slope (±SD) Intercept (±SD) Determination coeﬁciente (r2) Linear range (gmL−1)
305nm
Perchloric acid 5% y=9677x−910.8 9677±121.1 −910.8±556.9 0.9964 0.45–10
Liver y= 9279x+432.2 9279±87.21 432.2±381.8 0.9983 0.33–10
Kidney y=6858x+2404 6858±54.21 2404±256.3 0.9990 0.5–10
Electrochemical detection
Perchloric acid 5% y=54,113x−4772 53759±931.4 −4772±3814 0.9935 0.19–10
Liver y=54,260x+77.95 54260±674.8 77.95±2763 0.9966 0.21–10
Kidney y=42,409x+951.0 42409±426.4 951±1646 0.9975 0.11–10
Fig. 3. Stability study of -amanitin on several matrices, temperatures, and time-points. Values of -amanitin are represented as mean± standard deviation (SD) of three
independent samples. Each matrix was analyzed by diode array (DAD) and electrochemical (EC) after storage at different temperatures [room temperature (RT), 4 ◦C, −20 ◦C
and, −80 ◦C] over 1, 7 and 14 days. Stability of -amanitin was evaluated in (A,B) 5% perchloric acid, (C,D) liver and (E,F) kidney matrices. Statistical analysis was performed
using two-way ANOVA. If a statistical signiﬁcance was achieved (p<0.05), the Tukey multiple comparisons test was performed. Signiﬁcant differences (two-way ANOVA,
followed by the Turkey multiple comparisons test post-hoc test): ****p<0.0001 vs. RT, time=0min; ####p<0.0001 vs. 4 ◦C, time=0; $$$$p<0.0001 vs. 4 ◦C, time=7 days;
$$$p<0.001 vs. 4 ◦C, time=7 days; $ $p<0.01 vs. 4 ◦C, time=7 days; &&&&p<0.0001 4 ◦C vs −80 ◦C, time=7 days; &&&&p<0.0001 4 ◦C vs −20 ◦C, time=7 days; &&p<0.01 4 ◦C vs
−20 ◦C, time=7 days; +++ +p<0.0001 4 ◦C vs −80 ◦C, time=14 days; ++++p<0.0001 4 ◦C vs −20 ◦C, time=14 days.
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Table 3
Precision and accuracy results.
-amanitin (gmL−1) Intra-assay precision
RSDa (%) (n=6)
Inter-assay precision
RSDa (%) (n=18)
Recovery (%) RSD (%)(n=3)
305nm
Perchloric acid 5%
0.84 2.75 6.10
5 1.15 5.57
7.5 1.65 5.66
Liver
0.5 8.65 15.30 99.99 2.49
5 3.97 4.27 98.48 2.00
7.5 0.61 3.54 99.89 0.21
Kidney
0.82 8.16 11.59 101.06 2.13
5 2.18 6.30 99.42 1.05
7.5 1.73 2.63 99.69 0.90
Electrochemical detection
Perchloric acid 5%
0.84 2.13 3.91
5 2.64 5.22
7.5 1.64 10.70
Liver
0.5 2.27 7.49 99.87 3.41
5 1.65 6.36 99.80 1.03
7.5 0.55 9.72 96.87 3.21
Kidney
0.82 3.87 10.94 99.49 1.99
5 3.60 8.99 98.19 2.16
7.5 2.43 6.64 101.45 2.62
a Acceptance criteria: RSD±20%.
values for solutions of -amanitin in 5% perchloric acid, liver and
kidneymatrices are shown inTable2.All the linearity, rangeparam-
eters, and their related validation data are shown in Table 2. The
regressiondata for calibration curve shows good linear relationship
with r2 >0.990.
3.3.3. Recovery
Recovery from the spiked sampleswas determined as described
in Section 2.5.3. Results show an overall mean percent recovery of
above 96 % (Table 3).
3.3.4. Precision
The repeatability and the intermediate precision (intra- and
inter-assay precision) were calculated as the RSD of replicate sam-
ples at three concentration levels of -amanitin, as described in
Section 2.5.4.
The intra- and inter-assay precision for detection of -amanitin
in 5% perchloric acid, and rat liver and kidney matrices are pre-
sented in Table 3. As shown in Table 3, intra-assay precision for 5%
perchloric acid matrix ranged from 1.15% to 2.75% (DAD) and 1.64%
to 2.64% (EC) whereas the inter- assay precision ranged from 5.57%
to 6.10% (DAD) and 3.91% to 10.70% (EC). Intra-assay precision for
liver matrix ranged from 0.61% to 8.65% (DAD) and 0.55% to 2.27%
(EC)whereas the inter-assay precision ranged from3.54% to 15.30%
(DAD) and6.36% to 9.72% (EC). Finally, intra-assay precision for kid-
ney matrix ranged from 1.73% to 8.16% (DAD) and 2.43% to 3.87%
(EC)whereas the inter-assay precision ranged from2.63% to 11.59%
(DAD) and 6.64% to 10.94% (EC). Acceptable RSD values (lower than
20%) were obtained for all concentration and for both detectors
(DAD and EC), thus the developed method was sufﬁciently precise.
Table 4
LOD and LOQ values (expressed as gmL−1 or gg−1) computed according to dif-
ferent criteria.
Perchloric acid 5%
(gmL−1)
Liver
(gg−1)
Kidney
(gg−1)
305nm
LOD
Calibration Curve 0.150 0.110 0.160
Based on visual evaluation 0.050 0.050 0.125
LOQ
Calibration Curve 0.450 0.330 0.500
Based on visual evaluation 0.250 0.250 0.330
Electrochemical detection
LOD
Calibration Curve 0.060 0.070 0.040
Based on visual evaluation 0.015 0.015 0.050
LOQ
Calibration Curve 0.190 0.210 0.110
Based on visual evaluation 0.025 0.025 0.100
3.3.5. Sensitivity
LOD and LOQ were evaluated and the obtained data are shown
in Table 4. Based on visual evaluation, the LOD and LOQ values
for 5% perchloric acid were 0.050 and 0.250g.g−1 (DAD), and
0.015 and 0.025g.g−1 (EC), respectively. For liver matrix, the LOD
and LOQ values were 0.050 and 0.250g.g−1 (DAD) and 0.015
and 0.025g.g−1 (EC), respectively. For kidney matrix the LOD
and LOQ values were 0.125 and 0.330g.g−1 (DAD) and 0.05 and
0.100g.g−1 (EC), respectively. Based on the calibration curve, for
5% perchloric acid matrix, the LOD and LOQ values were 0.150
and 0.450g.g−1 (DAD) and 0.060 and 0.190g.g−1 (EC), respec-
tively; for liver matrix the LOD and LOQ values were 0.110 and
0.330g.g−1 (DAD) and 0.070 and 0.210g.g−1 (EC), respectively.
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Lastly, for kidney matrix, the LOD and LOQ values were 0.160 and
0.500g.g−1 (DAD) and 0.040 and 0.110g.g−1 (EC), respectively.
3.3.6. Matrix effect
The matrix effect was evaluated by comparing the slopes of
the calibration curves obtained when processing standard 5% per-
chloric acid solutions and deproteinized liver and kidney samples
spiked with standards in the same concentrations. No signiﬁcant
difference was found by comparing 5% perchloric acid and liver.
On the other hand, there is a statistically signiﬁcant difference
(p<0.0001) between the 5% perchloric acid standards and the -
amanitin renal spiked samples, showing a signiﬁcant matrix effect.
3.3.7. Stability
Stability of -amanitin was investigated using 5% perchloric
acid, liver and kidney matrices.-Amanitin in all matrices was sta-
ble at room temperature and 4 ◦C over a period of 24h, with no
signiﬁcant degradation observed (Fig. 3). On the other hand, in the
samples kept at room temperature, a degradation of -amanitin
was observed over the period of 14 days. Signiﬁcant degradation
was already observed at 7 days being more pronounced at 14 days.
Values of -amanitin declined to non-detectable concentrations at
the 7th day at room temperature. In contrast, a slow degradation
wasobserved in thecaseof-amanitin samples storedat4 ◦C.How-
ever, a signiﬁcant degradation was observed at 7 days being more
pronounced at 14 days. Excellent stability was obtained either at
−20 and −80 ◦C as it can be seen in Fig. 3. No signiﬁcant degrada-
tion of -amanitin in 5% perchloric acid, liver and kidney matrices
was detected after storing the samples 14 days at −20 and −80 ◦C.
Moreover three freeze-thaw cycles did not cause any signiﬁcant
degradation in 5% perchloric acid and in both biological matri-
ces analyzed. Overall the results show that -amanitin in tissue
samples is stable during storage, extraction and chromatographic
analysis. Moreover, we concluded that the samples can be safely
stored at −20 ◦C and can be subjected to at least three cycles of
freeze-thaw without signiﬁcant degradation of the analyte.
3.4. Method application
The established HPLC method was applied to human plasma.
Fig. 4 showsanECchromatogram(A) andachromatogramrecorded
at 305nm (B) of blank plasma and plasma spiked to contain 5g
mL−1 of -amanitin. There were no endogenous interfering sub-
stances in the samples.
3.5. ˛-Amanitin quantiﬁcation in kidney, liver and plasma after
administration of ˛-amanitin to rats
The concentrations of-amanitin in rat plasmaand tissueswere
determined after administration of a single intraperitoneal (10 or
21.4mgkg−1)dose toWistar rats. RepresentativeECchromatogram
and chromatogram recorded at 305nm of kidney and their respec-
tive spiking with -amanitin are show in Fig. 5. Table 5 shows the
valuesobtainedbyprocessing theplasmaand tissuesas indicated in
section2.4 and are expressed asgof-amanitin per g of protein in
the tissues samples and expressed as g mL −1 in plasma samples.
The highest overall concentrations in the tissues examined were
in the following order: kidneys > liver. No detectable values were
found in plasma. Peak identity was conﬁrmed by spiking samples
with -amanitin.
4. Discussion
Several methods are available in the literature for the analy-
sis and quantiﬁcation of -amanitin in different matrices, mainly
mushrooms [11–15], plasma [20,28,29] and urine [16,21–22,29]
Fig. 4. Representative EC chromatograms of (A) blank plasma and plasma spiked
to contain 5g mL−1 of -amanitin. Representative chromatograms recorded at
305nm of (B) blank plasma and plasma spiked to contain 5g mL−1 of -amanitin.
Table 5
Quantiﬁcation of -amanitin in real samples (plasma, liver, and kidney) from rats
injected with -amanitin.
Plasma(gmL−1) Liver(gg−1) Kidney(gg−1)
305nm
Rat (10mgkg−1 4h) N.D. 0.97 1.40
Rat (21.4mgkg−1 2h) N.D. N.D. 3.16
Rat (21.4mgkg−1 4h) N.D. 0.71 26.58
Electrochemical detection
Rat (10mgkg−1 4h) N.D. 1.00 1.66
Rat (21.4mgkg−1 2h) N.D. N.D. 4.00
Rat (21.4mgkg−1 4h) N.D. 0.80 33.74
N.D.: not detectable.
(Table 1) due to the toxicological importance of this amatoxin.
Research studies have been focused on the detection of-amanitin
in body ﬂuids for an early diagnosis of intoxications as to allow
the rapid application of therapy [16,19,22]. However, presently the
overall toxic mechanisms of -amanitin remain unclear, hindering
the development of new andmore effective antidotes, and relevant
forensic studies on -amanitin are scarce. Improved knowledge
of the toxicity mechanisms and the kinetics of this toxin will
help the development of more efﬁcient antidotes for A. phalloides
poisoning. Moreover, recent ﬁndings suggest that -amanitin is
emerging as an attractive new potent anticancer drug [10]. There-
fore, the efﬁcacy of -amanitin as an anticancer agent must be
scientiﬁcally validated, through animal experiments that include
pre-clinical pharmacokinetic and pharmacodynamic studies. To
comprehensively characterize the mechanisms of toxicity, pre-
clinical pharmacokinetics and efﬁcacy of -amanitin as anticancer
agent, a highly sensitive, accurate, and reproducible quantiﬁcation
method is required. To the best of our knowledge, there is only one
HPLC-UV developed study for analysis of -amanitin in liver and
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Fig. 5. (A) Representative EC chromatogram of rat kidney after an intraperitoneal
administration of 21.4mg kg−1 of-amanitin that was sacriﬁced 4h later. The same
sample was spiked with -amanitin. (B) Representative chromatogram recorded at
305nm of rat kidney after an intraperitoneal administration of 21.4mg kg−1 of -
amanitin thatwas sacriﬁced 2h later. The same samplewas spikedwith-amanitin.
kidney [29], whereas there is no study with EC detection for the
analysis of- amanitin in this biological tissues. Therefore, it is evi-
dent that there is a lack of HPLC-EC-UV methods for the detection
of -amanitin in liver and kidney, the target organs. The presence
of a 6- hydroxytryptophan residue in the molecule of -amanitin
suggested the possibility of detecting this compound through an
EC detector operating in an oxidative mode [22,28]. Herein, an iso-
craticHPLCmethodusingDADandECdetectorswas developed and
validated for the quantitative measurement of -amanitin in rat
liver and kidney tissues. This method has advantages over the pre-
viousmethods by providing an extraction procedure of-amanitin
from the tissue homogenates achieved by a unique deproteiniza-
tion step using 5% perchloric acid followed by centrifugation, thus
resulting in a simple, convenient and rapid separation of the ana-
lyte. Previously described extraction procedures of -amanitin in
liver samplesuseorganic solvents,methylene chloride andacetoni-
trile, being time-consuming and the resulting chromatograms are
quite complex showing several interferences [19]. Deproteiniza-
tion using 5% perchloric acid can be performed on any biological
sample and can be routinely applied in many laboratories all over
the world. Herein, our procedure was also efﬁcient with plasma
samples, which indicates that this simple deproteinization step
can be applied to other biological matrices. Moreover, clean chro-
matograms were obtained, thus improving the analysis. In our
method, the buffer of the mobile phase was also optimized. The
buffer capacity, the type of detectors used (DAD and EC), the sta-
bility of the solution, the solubility and the column were taken
into account. Both LC–EC studies available so far, used a mobile
phase composed of phosphate buffer and acetonitrile. One of the
major problems with phosphate buffers is the precipitation of
phosphates in the HPLC system. As an alternative, we used cit-
rate as a buffer of the mobile phase. Citrate can be used in a wide
range of pH (2.1 <pH<6.4) and provides low background noise,
which is very important in electrochemical analysis [24,27]. The
ratio of citrate: methanol (80:20): 0.46mM octanessulfonic acid
and the pH 5.5 were key to obtain good separation and resolution
of the -amanitin peak. Moreover, the short run time of 22min
enables a large number of samples to be analyzed in a short period
of time. Furthermore, the method was highly speciﬁc since liver,
kidney and plasma samples analyzed did not exhibited chromato-
graphic peaks corresponding to endogenous compounds co-eluting
with the target analyte. Calibration curves over the entire range
of concentrations were adequately described by 1/concentration
weighted quadratic regression of the peak–area ratios of - aman-
itin, with regression coefﬁcient r2 always greater than 0.994 in all
analytical runs. This shows that our method was linear and a broad
range of concentrations can be used. Extraction recovery at a con-
centrations ranging from 0.5 to 7.5g mL−1, results in an overall
mean percent recovery of above 96%. This recovery gives a great
deal of conﬁdence as this method can be applied into intoxicated
humans, in terms of forensic analysis as well as to post-mortem
tissues and therefore conﬁrm the etiology of symptoms.
Considering the intra-assay variations (expressed as RSD),
higher variability was found as the analyte levels were lower
(Table 3) whereas for inter-assay variations (expressed as RSD),
higher variability was found in the higher analyte levels (Table 3).
Results show an overall RSD of 15.30%, making the developed
method precise. The LOD and LOQ values were obtained using
two different criteria as to make it comparable to those methods
found in the literature (Table 4). The values based on visual eval-
uation are slightly lower than the LOD and LOQ calculated from
the linear regression parameters (Table 4). In previous reports,
the LOD was about 10ng mL−1 for urine by HPLC–UV [16], 2ng
mL−1 (corresponding to a signal-to-noise ratio of 2:1) for plasma
by HPLC-EC [28], although most of these methods are speciﬁc for a
certainmatrix. To thebest of our knowledge, only threemethodolo-
gies have been validated for -amanitin determination in the liver
[19,21,29]. Jaeger et al. developed a HPLC-UV method for analysis
of -amanitin in plasma, urine, feces, gastroduodenal ﬂuid, kidney
and liver [29]. The sample preparation involved a chemical step
with deproteinization and organic solvent treatment, and a selec-
tive cleanup and concentration step on reversed-phase pre-packed
cartridges. The LOD of this method was 5ngmL−1 in liver and kid-
neys. However, since the content was presented as ng mL−1 and
the authors did not describe the method and the analytical pro-
cedure for the determination of LOD, we cannot compare it with
our values. Leite et al. developed an analytical methodology of
UPLC–MS/MS following liver samplepreparationbyproteinprecip-
itation with organic solvents, and solid phase extraction procedure
and found a LODbased on signal-to-noise ratio 3:1 to be 10.9ngg−1
[21], whereas our LOD was 15ngg−1 (EC detection). Filigenzi et al.
described a LC–MS/MS/MS method for the analysis of -amanitin
in liver [19]. Liver was prepared by homogenization with aque-
ous acetonitrile and subsequent removal of acetonitrile was done
using methylene chloride. The aqueous phase was then extracted
usingmixed-modeC18/cation exchange solid phase extraction car-
tridges. The LOD in this method was 0.50ngg−1. It is evident that
the LODs in liver in the last two methods are lower than those
described in our work. It is well known that MS and MS/MS/MS
detectors offer highest sensitivity, however HPLC–MS instruments
are not available in many laboratories. Moreover, our method pro-
vided a unique step of deproteinization for sample preparation,
when compared to the multiple steps described in the mentioned
works. The concentration of -amanitin in liver and kidney tis-
sues poisoning cases analyzed by HPLC-UV show high variability
(0-1719ngg−1) [29], which indicates that our method is sensitive
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enough for the quantiﬁcation of -amanitin in liver and kidney
from suspected human intoxications.
The comparison between the twodetectors (DADandEC) shows
that the LOD and LOQ for -amanitin could be improved through
the use of an EC detector. Nevertheless, HPLC-EC instruments are
not available inmany laboratories. For that reason, validation using
UV detector was made since it is a more common instrument all
over the world. Moreover, it does not require a long period of sta-
bilization as it happens with EC detector.
Evaluation of the matrix effect shows that there is a signiﬁcant
difference between the HPLC response for -amanitin in 5% per-
chloric acid and the response for the -amanitin in kidney matrix.
This is probably due to residual components of the kidney matrix,
thus demonstrating the importance of the study on equivalent
matrices. On the other hand, no statistical difference was found
between 5% perchloric acid and liver matrix.
The results of all stability tests indicate that -amanitin in 5%
perchloric acid and tissue samples was stable during sample stor-
age, extraction and chromatographic analysis. Evaluation of more
than one freeze–thaw cycle was performed, since samples may
require multiple analysis. Three freeze thaw cycles also did not
cause any signiﬁcant degradation in all matrices when stored in
acidic matrix. The tissue collection can be done after acidiﬁcation
since our data show that - amanitin was stable at room temper-
ature and 4 ◦C over a 24 hour period. No liquid nitrogen or urgent
freezing seems to be required, making this method very practical
and reliable in all laboratories and clinical settings.
As to prove the applicability of our method, we performed an
in vivo study with different -amanitin doses and sacriﬁce times.
After the intraperitoneal administration of a single dose of -
amanitin (10 or 21.4mg/kg) to Wistar rats, the validated analytical
method was successfully applied. In rats, there are no -amanitin
pharmacokinetic data available at this point. Therefore, based on
in vivo studies in murine models [9,30], we selected the 2 and 4h
post-administration periods to perform sample collection. The tox-
icokinetic of -amanitin has been studied in intoxicated humans
and dogs and shows to have a short half-life (it is totally elimi-
nated from the blood after 41.02min), being widely distributed to
target tissues (liver and kidney). Our method was able to detect
-amanitin in several samples. The short plasma half-time of -
amanitin was conﬁrmed, as no analyte was found in plasma. Our
results show higher levels of total -amanitin in kidney than
in liver. These differences may be explained by pharmacokinetic
proprieties of-amanitin in this animalmodel, whichmainly accu-
mulates in the kidney.
Of interest, this method was also successfully applied to quan-
tify -amanitin in human plasma since there were no endogenous
substances co-eluting with the peak of interest. Taking this under
consideration, we suggest that this method can be used for early
diagnosis ofA. phalloidespoisoning, tissues analysis andother phar-
macokinetic studies. In fact, thismethod is a suitable tool to support
in vivo toxicokinetic studies designed to elucidate the mechanisms
of toxicity of -amanitin, being able to help in the development of
novel and potent antidotes against amatoxin’s poisoning.
5. Conclusion
A selective and sensitive HPLC method using DAD and EC
detectors has been developed and validated for the quantitative
measurement of-amanitin in 5% perchloric acid, rat liver and kid-
ney. The extraction of -amanitin from tissue homogenates was
achieved by a simple deproteinization step with a high recovery
of the analyte. Validation was carried out by the evaluation of the
most relevant parameters for checking the quality of the method.
The method proved to be linear in the concentration range studied,
as well as it showed to selective, accurate, precise and sensitive. All
stability tests indicated that -amanitin was stable during sample
storage, extraction, and chromatographic analysis. Moreover, this
method was successfully applied to real samples, after- amanitin
administration to Wistar rats. Taken together, these characteris-
tics combined with a short chromatographic run time of 22min,
allow this method to be easily applied for the determination of
-amanitin in liver and kidney and other biological samples. This
method provides a convenient tool for the future toxicological and
clinical studies involving - amanitin.
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